Literature DB >> 498147

Disposition and distribution of platinum following parenteral administration of cis-dichlorodiammineplatinum(II) to animals.

C L Litterst, A F LeRoy, A M Guarino.   

Abstract

After iv administration of cis-dichlorodiammineplatinum(II) (cis-platinum) to animals, plasma levels of platinum decline in a biphasic manner, with a distribution phase (alpha) half-life of minutes and an elimination phase (beta) half-life of days. Urinary excretion of platinum is extensive on the first day after drug administration with a final urinary recovery of 70%--90% of the administered dose. Platinum is initially distributed to nearly all tissues with the highest levels appearing in kidney, liver, ovary, uterus, skin, and bone. There is no preferential uptake of platinum into tumor, although the presence of a tumor may alter the rate of platinum excretion and the extent of whole-body retention. No effect is seen on hepatic microsomal drug metabolism after ip administration of cis-platinum to rats. Platinum is excreted more rapidly from hydrated animals than from controls although total urinary recovery of platinum is nearly equal in both groups. Most analogs of cis-platinum appear to follow the same elimination and distribution patterns as cis-platinum itself.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 498147

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  30 in total

1.  Prediction of nephrotoxicity induced by cisplatin combination chemotherapy in gastric cancer patients.

Authors:  Hyung Hwan Moon; Kyung Won Seo; Ki Young Yoon; Yeon Myung Shin; Kyung Hyun Choi; Sang Ho Lee
Journal:  World J Gastroenterol       Date:  2011-08-14       Impact factor: 5.742

2.  Acute and long-term nephrotoxicity of cis-platinum in man.

Authors:  S Groth; H Nielsen; J B Sørensen; A B Christensen; A G Pedersen; M Rørth
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 3.  Cisplatinum: a review, with special reference to cellular and molecular interactions.

Authors:  C L Litterst
Journal:  Agents Actions       Date:  1984-12

4.  Platinum concentration in human tumors of head and neck, uterine cervix, and breast following treatment with cisplatin.

Authors:  B Hecquet; P Vennin; C Fournier; J L Lefebvre; A Caty; J Bonneterre; L Adenis; A Demaille
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

5.  Effects of intralesional injection of cisplatin dissolved in urografin and lipiodol on Ehrlich ascites tumor and normal tissues of CD-1 mice.

Authors:  J E Landrito; K Yoshiga; K Sakurai; K Takada
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

6.  Permeability change and brain tissue damage after intracarotid administration of cisplatin studied by double-tracer autoradiography in rats.

Authors:  S Sugimoto; Y L Yamamoto; S Nagahiro; M Diksic
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

7.  Pharmacokinetics and tissue distribution of liposome-encapsulated cis-bis-N-decyl-iminodiacetato-1,2-diaminocyclohexane-platinum (II).

Authors:  J Lautersztain; R Perez-Soler; A R Khokhar; R A Newman; G Lopez-Berestein
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

8.  Polybutylcyanoacrylate nanoparticles and drugs of the platinum family: last status.

Authors:  Dashti Rahmat Abadi Fatemeh; Hasan Ebrahimi Shahmabadi; Anita Abedi; Seyed Ebrahim Alavi; Fatemeh Movahedi; Maedeh Koohi Moftakhari Esfahani; Tahereh Zadeh Mehrizi; Azim Akbarzadeh
Journal:  Indian J Clin Biochem       Date:  2013-07-23

9.  Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity.

Authors:  K K Filipski; R H Mathijssen; T S Mikkelsen; A H Schinkel; A Sparreboom
Journal:  Clin Pharmacol Ther       Date:  2009-07-22       Impact factor: 6.875

10.  Physiological pharmacokinetic modeling of cis-dichlorodiammineplatinum(II) (DDP) in several species.

Authors:  F G King; R L Dedrick; F F Farris
Journal:  J Pharmacokinet Biopharm       Date:  1986-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.